Magnetic Resonance Spectroscopy in the Psychosis Risk Syndrome

磁共振波谱检查在精神病风险综合征中的应用

基本信息

批准号：
8703803
负责人：
Stephan F Taylor
金额：
$ 19.44万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-07-19 至 2016-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8703803
关键词：
Accounting Address Affect Age Antipsychotic Agents Behavior Benzodiazepines Biological Assay Brain Brain region Chronic Clinical Data Disease Distress Dorsal Early Diagnosis Emotions Exhibits Foundations Functional Imaging Functional Magnetic Resonance Imaging Funding General Population Glutamates Glutamine Goals Image Individual International Interneurons Intervention Knowledge Link Longitudinal Studies Magnetic Resonance Spectroscopy Measurement Measures Medial Mediator of activation protein N-Methyl-D-Aspartate Receptors Neurobiology Neurotransmitters Occipital lobe Outcome Paranoia Patients Persons Pharmaceutical Preparations Phenotype Prefrontal Cortex Preventive Intervention Process Psychotic Disorders Publishing Recruitment Activity Relative (related person)Reporting Research Role Schizophrenia Signal Transduction Site Speech Syndrome System Testing Therapeutic Therapeutic Intervention Wood material Work Youth attenuated psychosis syndrome blood oxygen level dependent blood oxygenation level dependent response clinical infrastructure design experience falls first episode psychosis gamma-Aminobutyric Acid help-seeking behavior high risk in vivo prevent programs psychotic symptoms public health relevance theories therapy design trait young adult

项目摘要

DESCRIPTION (provided by applicant): The concept of psychosis has shifted in recent decades, as evidenced by an intensive international effort aimed at identifying and treating youth at high risk of psychosis and emerging data that subclinical psychotic symptoms appear in the general population. Individuals with an 'attenuated psychosis syndrome' (APS) present with low levels of reality distortion (unusual thought content, perceptual aberrations, suspiciousness/paranoia), in addition to disorganized speech/behavior, subjective distress and clinical help- seeking. The syndrome is phenotypically continuous with schizophrenia and a critical opportunity in which to study pathophysiological mechanisms that may be common to both APS and schizophrenia. One important potential mechanism may be found in inhibitory GABAergic and excitatory glutamatergic systems. Magnetic resonance spectroscopy (MRS) has enabled the regional measurement of GABA and glutamate/glutamine concentrations, permitting the in vivo assay of these neurotransmitters. Unmedicated patients with schizophrenia have shown elevations of Glx (glutamate/glutamine concentration) and GABA levels in the medial prefrontal cortex (mPFC), a region of the brain implicated in functional and structural imaging studies in schizophrenia and APS. We found the mPFC to exhibit greater sensitivity to benzodiazepine challenge in chronic psychotic patients, suggesting that GABAergic abnormalities. A critical question is whether these abnormalities may be detected in the APS state, which this exploratory R21 proposal will address by measuring cortical GABA and Glx in young persons with APS, compared to matched healthy control subjects and first episode psychosis (FEP) patients. In Aim 1, we will examine GABA and Glx levels in APS individuals in the mPFC and occipital cortex, testing the prediction that GABA and Glx levels will be elevated in APS subjects in the mPFC, relative to healthy controls and medicated FEP patients. In contrast, GABA and Glx are predicted to be reduced in the occipital cortex of both APS and FEP subjects. In Aim 2, we will assess mPFC function in APS individuals and test correlations with GABAergic and Glx signal from this same region. We predict that GABAergic and Glx signals will be inversely correlated with mPFC BOLD signal in the APS patients (but not medicated FEP patients). The anticipated impact of this R21 is three-fold: 1) An essential first step required before an R01-level proposal can examine baseline GABA and Glx as predictors of outcome (conversion to psychosis as well as clinical improvement), 2) An essential first step for a longitudinal study that will examine change in GABA and Glu and associations with outcome; and 3) A mechanistic rationale for designing therapeutic interventions that target GABA/Glx systems in APS.

描述（由申请人提供）：近几十年来，精神病的概念发生了变化，这是由旨在识别和治疗患有精神病高风险和新兴数据的青年的强化努力所证明的，而亚临床精神病症状出现在一般人群中。患有“衰减精神病综合征”（AP）的个体表现出低水平的现实失真（异常思想内容，感知畸变，可疑性/偏执狂），此外，语音/行为混乱，主观困扰和寻求临床帮助。该综合征在表型上与精神分裂症是连续的，也是研究APS和精神分裂症可能共有的病理生理机制的关键机会。在抑制性GABA能和兴奋性谷氨酸能系统中可以找到一种重要的潜在机制。磁共振光谱（MRS）使GABA和谷氨酸/谷氨酰胺浓度的区域测量允许对这些神经递质的体内测定。精神分裂症的未药物患者已显示出内侧前额叶皮层（MPFC）中GLX（谷氨酸/谷氨酰胺浓度）和GABA水平的升高，这是大脑的一个区域，与精神分裂症和APS的功能和结构成像研究有关。我们发现MPFC在慢性精神病患者中对苯二氮卓挑战表现出更大的敏感性，这表明GABA能异常。一个关键的问题是，与匹配的健康对照对象和第一集的心理医生（FEP）患者相比，该探索性R21提案将通过测量APS的皮质GABA和GLX来解决这些异常，该提案将通过测量APS的皮质GABA和GLX来解决。在AIM 1中，我们将检查MPFC和枕皮层中APS个体中的GABA和GLX水平，以测试MPFC中APS受试者的GABA和GLX水平相对于健康对照组和药物FEP患者的APS受试者的预测。相比之下，预计在AP和FEP受试者的枕叶皮层中，GABA和GLX被预测会减少。在AIM 2中，我们将评估APS个体中的MPFC功能，并测试与来自同一区域的GABA能和GLX信号的相关性。我们预测，APS患者中的GABA能和GLX信号将与MPFC BOLD信号成反比（而不是药物FEP患者）。该R21的预期影响是三倍：1）在R01级建议可以检查基线GABA和GLX之前，必需的第一步是结果的预测因素（转换为精神病以及临床改进），2）纵向研究的重要第一步，该研究将检查GABA和GLU和GLU和GLU和GLU的变化以及结果的变化； 3）一种机械基本原理，用于设计针对AP中的GABA/GLX系统的治疗干预措施。